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  In this paper, ultrasound contrast agents based 
on a high molecular polymer-poly lactic acid (PLA) 
and loaded with Hydroxycamptothecin (HCPT) 
were prepared by combining ultrasound method 
and a Shirasu Porous Glass (SPG) membrane 
emulsification technique. A special focus was on 
the optimization of production of HCPT-PLA 
microbubbles. Different factors, such as the power 
and the time of ultrasonic action, the ratio of inner 
aqueous phase against outer oil phase, and the 
concentration of PLA were evaluated, and the 
average size of HCPT-PLA microbubbles, the drug 
carrying efficiency, as well as the acoustically- 
triggered drug release at 3kHz ultrasound were 
determined. The study showed that the HCPT-PLA 
microbubbles prepared using our optimized 
conditions, were sphere-like in shape with a mean 
diameter of 1-7µm. The drug loading efficiency 
reached up to 56.48%. In vitro, the drug release of 
HCPT-PLA microbubbles increased significantly 
at 3kHz ultrasound for 30s compared with that of 
ultrasound-free condition. In conclusion, the 
HCPT-PLA microbubbles has the characteristics 
desirable for an intravenously administered 
ultrasound contrast agent for further clinical use.  
 
Keywords.Ultrasound contrast agent; Poly 





Ultrasound contrast agents (UCA) can provide 
enhanced scattering signatures to distinguish the 
acoustic scattering signatures of blood from the 
surrounding tissues [1, 2]. The first-generation 
UCA were not ideal for the large size and 
instability. In recent years, microbubble encapsulat
ed by a thin layer coat become the most extensive 
applification compared with other contrast agents 
[3]. The coat-forming materials of microbubbles 
have phospholipids compounds, albumin, 
carbohydrate, non-ionic surfactant and the 
biodegradable polymeric-molecule polymer and so 
on[4,5]. Microbubbles encapsulated with polymer 
have uniformly and tight size distribution, 
compressibility, more stability in vivo, high 
natural resonance frequency, and acquired ideal 
scattering intensity under high emitted frequency 
[6,7,8,9]. It is assumed as the best contrast agents 
now and become a study hotspot.Microbubbles not 
only used for ultrasound clinical diagnostics, but 
also used for targeting or controlling drug release, 
because it will result in bubbles collapse ,and cell 
membrane permeability or absorption increase 
when the focus insonated by ultrasound [10,11,12]. 
There are many advantages when microbubble 
ultrasound agents were used in drug-carrying 
delivery system. Drug carried by stabilized 
microbubble could extend the half time in vivo and 
enhance the targeting property, eliminate 
unwanted immune response, stabilize the drug 
concentration in blood and reduce the toxicity and 
side effects.[13,14].  
Poly lactic acid (PLA) is a popular biodegrade- 
able and bioconsistent polymer, that has been 
approved by the FDA for use in sutures, 
microcapsule, micobubble and others in 
intravenous injection.PLA can slowly be degraded 
by non-enzymatihydrolysis into lactic acids which 
is a natural body metabolite and can be degraded 
by enzymes to carbon dioxide and aqueous[15,16].  
The drug loading microbubbles targeted in vivo 
is determined by their size. Microbubbles exceed 
7µm in diameter are removed from blood in the 
lung circulation; while below 5µm they can flow 
across the capillary and are captured by the liver or 
spleen finally. So to use for drug loading, 
microbubble must be prepared with suitable sizes 
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depended on different targetingtissues or 
organs[17,18]. 
Hydroycamptothecin(HCPT) is cytotoxic 
anti-tumor drug and a cell period restraining drug. 
It mainly acts on S period, and has selective 
inhibition on Toposomerases(TOPO1), It is effect- 
tive against idopathic liver cancer, stomach cancer, 
adenoid epithelium on head or neck ,leukemia, 
cancer of rectum, and bladder cancer et al[19]. 
However it has a short half-life and some adverse 
effects. In this paper, we optimized the preparation 
of encapsulated-HCPT, gas-filled PLA microbubbl 
es ultrasound contrast agents and integrated its 
drug releasing behivor in order to set up a drug 
targeting delivery model for toxic and short 
half-life drugs based on microbubble combining 
ultrasound. 
 
2. Material and methods 
 
2.1.Preparation of PLA microbubble by 
ultrasound double emulsion technique 
 
Preparation process: 1ml inner aqueous phase 
(W1) was injected into 10ml CH2Cl2 oil phase in 
which dissolved PLA10000 and 1% Span80, while 
the ultrasound generator was used to form a w1/o 
primary emulsion. Then, this emulsion was 
injected into outer aqueous phase(w2) which 
contained 0.5%PVA, while the ultrasound 
generator was used to form w1/o/w2 double 
emulsion. Whereafter, the double emulsion was 
poured into 10 times volume of 10% PVA solution. 
Then, the liquor was churned up at 200rpm/min 
over night holding at 40 on a magnetic force 
blender before centrifugated at 2000g for 20min. 
The microbubbles sediment were washed 3 times 
with distilled water after collected, and then were 
dried in vacuum refrigerant drier( Labconco Free 
Zone）before filled with air. The size distribution 
and figure of microbubbles were observed and 
measured with electron microscope (Philips XL-30) 
and Zetasizer (zetasizer nano series).  
The power and time of ultrasound to prepare the 
w1/o emulsion, the concentration of PLA10000 , 
the rate of inner aqueous phase against outer oil 
phase, the power and time of ultrasound to prepare 
w1/o/w2 double emulsion, and the concentration 
of NH4HCO3 in the inner aqueous phase were all 
investigated just as the table1 shows. 
Table 1. The investigated factors for the preparation of PLA microbubbles 








1 80/10/2 200/10/2 0.0125 1：5：100 0.0025 
2 80/10/5 200/10/5 0.025 1：10：100 0.005 
3 80/10/10 200/10/10 0.05 1：15：100 0.01 
4 80/10/15 200/10/15 0.1 1：20：100 0.02 
Num.: Number. 
U.p.t. for w1/o E.(w.s.t): ultrasound power and 
time for w1/o emulsion (watt.second.times). 
U.p.t. for w1/o/w2 (w.s.t): ultrasound power and 
time for lipiodol double emulsion 
(watt.second.times). 
CPLA10000（g/ml）:Concentration of PLA10000
（g/ml）in outer oil phase. 
RW1/O/W2: Rate of inner aqueous: outer oil: outer 
aqueous. 
CNH4HCO3（g/ml）: Concentration of NH4HCO3 in 
the inner aqueous phase（g/ml）. 
 
2.2.Preparation of PLA microbubbles by 
the method of ultrasound cooperated with 
microporous membrane emulsifier 
 
Preparation process: the preparation of the w1/o 
emulsion was based on the optimized method of 
2.1.Then, the w1/o emulsion was poured into the 
pressure cabin of microporous membrane 
emulsifier which was fixed a SPG membrane of 
1.1µm. Appropriate and equal pressure was given 
by the high pressure and high purified N2 to press 
the w1/o emulsion through SPG membrane into 20 
times volume of circularly flowing 1% PVA 
solution. Then we churned it up at 200rpm/min 
over night holding at 40 on a magnetic force 
blender. Collected the microbubbles sediment and 
washed 3 times with distilled water after 
centrifugated at 2000g for 20min. Dried it in 
vacuum refrigerant drier before filled with air. The 
size distribution and figure of microbubbles were 
observed and measured with electron microscope 
and zetasizer. 
 
2 . 3 . P r e p a r a t i o n  o f  H C P T – P L A 
microbubbles 
 
The microbubbles were prepared with the 
optimized method of 2.2, and the inner aqueous 
phase was replaced by 0.9% sodium chloride and 
0.0025g/ml NH4HCO3 solution into which was 
dissolved HCPT in different concentration of 
401
1mg/ml, 2mg/ml, 3mg/ml, 4mg/ml and 5mg/ml 
respectively. And then try to probe the relationship 
between HCPT concentration and microbubbles 
drug loading capacity or encapsulation rate. 
A passel of 50mg PLA microbubbles was 
dissolved into 0.5ml CH2Cl2, then the HCPT was 
extracted out with 0.1mol/l sodium hydroxide 
solution to mensurate OD384nm. The 
concentration of HCPT was calculated referring to 
the standard curve between HCPT concentration 
and OD384nm. The calculation methods of the 
drug loading capacity and encapsulation rate of 
microbubble were refered to follow formulae. 
Drug loading capacity = WHCPT / Wm×100%; 
Encapsulation rate = Mdlc / Tdlc×100% 
WHCPT: Weight of loading HCPT 
Wm: Weight of microbubbles 
Mdlc:Mensurated drug loading capacity 
Tdlc: Theoretic drug loading capacity 
 
2.4.Drug releasing behavior in vitro of 
insonated with ultrasound or not 
 
A passel of 50mg PLA microbubbles was 
dispersed into 10ml of 0.9% sodium chloride 
solution, and was churned up on the magnetic 
force blender keeping the speed of 100rpm/min in 
37. 0.5ml solution was extracted every time after 
0.5h, 3h, 24h, 72h and 168h, respectively, then the 
samples were centrifugated at 2000g for 20min to 
extract the upper liquid. The HCPT concentration 
of extraction was calculated by the standard curve 
between HCPT concentration and OD384nm. Drug 
spontaneous releasing behavior in vitro was 
described with the relationship between 
cumulative concentration of released HCPT and 
time. The microbubbles dispersive buffer was 
prepared by the same way as upwards, and 0.5ml 
solution was extracted from each before the first 
operated and after operated by ultrasound in the 
4frequency of 3.5MHz, and the average intensity 
per cross section of 1.0W/cm2 for 30s,60s or 90s 
every time.  
The HCPT concentration of extraction was 
calculated by the same way as upwards, and drug 
releasing behavior in vitro of being insonated with 
ultrasound was described with the relationship 
between cumulative concentration of released 
HCPT and insonated times.  
 
3.Results and discussions  
 
3.1.Preparation of PLA microbubbles by 
ultrasound double emulsion technique 
 
Character of the prepared PLA microbubbles 
was effected by the ultrasound power and time for 
w1/o emulsion, ultrasound power and time for 
double emulsion, concentration of PLA10000, the 
volume rate of inner aqueous:outer oil: outer 
aqueous and the concentration of NH4HCO3 in the 
inner aqueous phase.  
When the power/time/times of ultrasound for 
w1/o emulsion was low to 80w/10s/2t, the emul-
sion was unstable and the prepared microbubbles 
were too big and distributed in a large range. 
While it was up to 80w/10s/5t, the diameter of 
microbubbles can be controlled in 7µm, but too 
high of power/time/times over 80w/10s/10t will 
decreased the uniformity of microbubbles size. 
Microbubbles size were effected observably by 
the power/time/times of ultrasound for w1/o/w2 
double emulsion. The higher power/time/times 
always leaded to smaller size of microbubble. 
When the power/time/times was 200w/10s/2t,the 
size of some microbubbles were over 50µm, while 
it was up to 200w/10s/5t,the size was controlled in 
7um, and the size decreased to about 0.1µm while 
the power/time/times increased to 200w/10s/15t.  
Concentration of PLA10000 was the major 
element to affect the thickness and smoothness of 
the microbubbles’ shell. when it was 0.0125g/ml, 
some of the microbubbles’ shell were too thin to 
split, however, when it was increased to 
0.05g/ml,the outer oil phase seems viscid and the 
microbubbles were out of sphere and smooth. 
While the concentration was up to 0.1g/ml, the 
PLA couldn’t be dissolved into CH2Cl2 entirely, 
and no Microbubble but something nubbly were 
prepared. The results showed the best 
concentration of PLA10000 was about 0.025g/ml.  
The diameter and amount of the pores on 
microbubbles’ shell were both decided by the 
concentration of NH4HCO3 .when NH4HCO3 
concentration was 0.0025g/ml，the great mass of 
microbubbles were just one pore on the shell. The 
more NH4HCO3 was dissolved into inner aqueous 
phase the more pores would be distributed on the 
microbubbles’shell. 
The thickness of the microbubbles’ shell was 
effected by the rate between the volume of inner 
aqueous phase and outer oil phase as well as the 
concentration of PLA10000. When the rate was 1：
5, a part of the microbubbles was breaked which 
would certainly decrease the drug loading capacity 
and encapsulation rate of microbubbles. While the 
rate was low to 1:15, the shell of microbubbles 
was too thin and coarse as well as the rate’s of 
1:10. while the rate was 1:20, the microbubbles 
were out of sphere because the shell was too thin.  
According to the results upwards, the feasible 
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method of preparing PLA microbubbles with a 
tight size distribution (from 1 to 7µm) and smooth 
surface was got as follows: adopting the same 
preparation processing as 2.1 described, dissolving 
0.0025g NH4HCO3 into 1ml distilled water as 
inner aqueous phase, and 0.25g PLA10000 into 
10ml CH2Cl2 as outer oil phase to which was 
dispersed 0.1ml Span80, and keeping the 
ultrasound working at 25kHz for 80w/10s/5t while 
prepare the first w1/o emulsion and working at 
25kHz for 200w/10s/5t while prepare the w1/o/w2 
double emulsion, filling air into the prepared 
microbubbles after dried in vacuum refrigerant 
drier, observing and measuring the size 
distribution and figure of microbubbles with 
electron microscope and zetasizer.  
The electron microscope photograph (figure.1) 
 
shows that the diameter of microbubbles was 
distributed from 1 to 7µm, and the surface of the 
microbubbles is smooth as well as just one or no 
pore is on the shell.  The microbubbles size 
distribution measured by zetasizer shows as 
graph1.The size distribution of the microbubbles 
was showed as graph1.19.5% of the microbubbles 
were blonged to peak 1 with the mean diameter of 
238.1nm,and 34.3% were blonged to peak 2 of 
1713nm,and 46.2% were blonged to peak 3 of 
3961nm and no microbubble’s diameter was 
bigger than 7000nm. 
 
3.2.Preparation of PLA microbubbles by 
the method of ultrasound combining a 
Shirasu Porous Glass (SPG) membrane 
emulsification technique 
 
The prime w1/o emulsion was prepared by 
ultrasound emulsification ， dissolving 0.0025g 
NH4HCO3 into 1ml distilled water as inner 
aqueous phase, and 0.25g PLA10000 into 10ml 
CH2Cl2 as outer oil phase to which was dispersed 
0.1ml Span80, and keeping the ultrasound working 
at 25kHz for 80w/10s/5t while injecting the inner 
aqueous phase into outer oil phase.  
 
The size distribution of microbubbles was 
dominated by the N2 pressure while the diameter of 
pores in SPG microporous membrane were aptotic 
of 1.1µm. The appropriate pressure of N2 was 
about 30kPa, on which the prime w1/o emulsion 
can equably permeate the SPG microporous 
membrane, and the microbubbles were prepared 
with a narrow size distribution. results showed as 
fig2 and graph2 that 93.6% microbubbles blonged 
Figure 1.Electron microscope photograph of 
PLA microbubble produced by the method of 















Graph1.Size distribution by volume of PLA 

















Graph2: Size distribution of PLA microbub-
ble prepared by the method of ultrasonic 
cooperated with micromembrane emulsifier. 
Figure 2．Electron microscope photograph of
PLA microbubbles produced by the method 
of ultrasound combining a Shirasu Porous 
Glass (SPG) membrane emulsification 
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to peak2 of the mean diameter of 4124nm without 
microbubbles bigger than 7000nm and 6.4% 
microbubbles blonged to peak1 of 274nm. 
 
3.3.Preparation of PLA microbubbles 
carried HCPT 
 
3.3.1.Relationship between inner aqueous phase 
HCPT concentration and drug loading capacity 
or encapsulation rate of microbubbles 
The standard curve and equation between HCPT 
concentration and OD384nm was showed as graph3. 
The relationship between HCPT concentr- 
ation of inner aqueous phase and microbubbles 
drug loading capacity or microbubbles 
encapsulation rate of PLA microbubbles were 
showed on table2, graph4 and graph5. Results 
show that both the drug loading capacity and 
encapsulation rate were increased with the HCPT 
concentration before 4mg/ml, at which point them 
both on the top of 1.13% and 56.48%, and then 





Table 2.Relationship between HCPT concentration 




3.3.2.Drug releasing behavior in vitro 
insonated with ultrasound or not 
 
Drug releasing behavior in vitro of 
microbubbles was showed as table3 and graph6 
that the cumulative percent of drug spontaneous 
released in vitro was increased with the prolonger 
of time when the time was prolonged to 168h. The 
cumulative percent of drug released was 64.14%. 
The cumulative percent of drug released was 
increased with the enhancing of ultrasound work. 
While the microbubbles were treated with 
ultrasound for 4 times of 30sec (total 120sec.) 
every time at 3.5MHz ,the percent of drug released 
was cumulated to 68.49%. While it was treated for 
4 times of 60sec. (total 240sec.) every time, the 
percent of drug released was cumulated to 86.97%. 
and while the it was treated for 3 times of 
90sec(total 270sec.) every time, the percent of 
drug released was cumulated to 94.37%. However, 
treated it for 4 times of 90sec (total 360sec.) every 
ConcentrationHCPT (mg/ml) 1 2 3 4 5 
Encapsulation rate(％) 14.02 34.79 48.08 56.48 20.89 
Drug loading capacity(％) 0.17 0.28 0.77 1.13 1.04 















Graph 3.Standard curve between
HCPT concentration and OD384nm 
Graph 5. Relationship between HCPT
concentration of  inner aqueous phage 
























Graph 4.Relationship between HCPT
concentration of inner aqueous phage




























time, the percent of drug released was only 
cumulated to 94.81%, which seems no more drugs 
could be released from microbubbles. 
 











0 11.52 12.61 8.26 22.40 
1 12.17 11.09 21.96 45.88 
2 20.44 54.14 62.84 87.84 
3 26.53 67.84 77.62 94.37 
4 64.14 68.49 86.97 94.81 
T/S: ultrasound treating times of sequence of sampling. 
PD.S.R.: cumulative percent of drug spontaneous releasing in vitro. 
PD.R.S.30: cumulative percent of drug releasing treated with B-ultrasound for 30sec. every time in vitro. 
PD.R.S.60: cumulative percent of drug releasing treated with B-ultrasound for 60sec. every time in vitro. 
PD.R.S.90: cumulative percent of drug releasing treated with B-ultrasound for 90sec. every time 
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Ultrasound treating times /sequence




















Cumulative percent of drug spontaneous releasing
treated with ultrasound for 90sec. every time in vitro
Cumulative percent of drug spontaneous releasing
treated with ultrasound  for 60sec. every time in
vitro
Cumulative percent of drug spontaneous releasing
treated with ultrasound or 30sec. every time in vitro






Drug carrying ultrasound microbubble has been 
deemed as a new carrier for drug targeting and 
controlling delivery. To target in vivo, the 
microbubbles must be controlled under 7µ m in 
diameter to pass the lung circulation. When drug 
carrying ultrasound microbubbles were injected 
into vein and focus was scanned by ultrasound in a 
appropriate frequency, the drug will be delivered 
mostly to the targeted focus. So, the focus has a 
high drug concentration against the low drug 
concentration in blood.  
Our research shows that the diameter of the 
microbubbles prepared with ultrasound double 
emulsion technique were controlled under 7µm, 
therein, the diameter of 19.5%, 34.3% and 46.2% 
microbubbles were around 238.1nm, 1713nm, and 
3961nm respectively. However, 93.6% 
microbubbles prepared by the method of 
ultrasound cooperating with microporous 
membrane emulsifier was around 4124nm and no 
one bigger than 7000nm besides 6.4% 
microbubbles was around 274nm. 
So, we consider that the microbubbles can be 
used as drug carrier both prepared by the method 
of ultrasound double emulsion and the method of 
ultrasound cooperating with microporous 
membrane emulsifier. While, the microbubbles 
prepared by the latter are better than the first’s. we 
also find that the time of HCPT spontaneously 
releasing from PLA microbubbles in vitro can be 
kept over 1 week and ultrasound can evidently 
accelerate the HCPT releasing from PLA 
microbubbles in vitro.  
Based on the results of upwards we are sure that 
the drug releasing behavior in vivo insonated with 
ultrasound or not should be more interesting and 
complex. The further investigation of drug 
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